| 17/11/25 | 15:00:01 | 17 Nov 2025 | | Holding(s) in Company | RNS |
| 14/11/25 | 11:00:00 | 14 Nov 2025 | | Director/PDMR Shareholding | RNS |
| 10/11/25 | 15:00:00 | 10 Nov 2025 | | Director/PDMR Shareholding | RNS |
| 06/11/25 | 07:00:10 | 6 Nov 2025 | | 9M and Q3 2025 results | RNS |
| 03/11/25 | 16:00:00 | 3 Nov 2025 | | Result of General Meeting | RNS |
| 03/11/25 | 15:00:01 | 3 Nov 2025 | | Total Voting Rights | RNS |
| 28/10/25 | 07:05:00 | 28 Oct 2025 | | Director Declaration | RNS |
| 28/10/25 | 07:00:09 | 28 Oct 2025 | | Koselugo (selumetinib) approved in the EU | RNS |
| 22/10/25 | 07:00:09 | 22 Oct 2025 | | Tezspire Approved in EU for CRSwNP | RNS |
| 20/10/25 | 07:05:00 | 20 Oct 2025 | | US FDA Approves Tezspire in CRSwNP | RNS |
| 20/10/25 | 07:00:05 | 20 Oct 2025 | | Positive CHMP opinion for subcutaneous Saphnelo | RNS |
| 13/10/25 | 07:00:05 | 13 Oct 2025 | | Agreement with US Govt to lower medicine prices | RNS |
| 07/10/25 | 07:00:09 | 7 Oct 2025 | | Baxdrostat met primary endpoint in Bax24 Ph3 trial | RNS |
| 06/10/25 | 07:30:01 | 6 Oct 2025 | | Datroway improved OS and PFS in TROPION-Breast02 | RNS |
| 01/10/25 | 15:00:01 | 1 Oct 2025 | | Total Voting Rights | RNS |
| 29/09/25 | 07:30:01 | 29 Sept 2025 | | Enhertu improved IDFS in early BC in DB-05 | RNS |
| 29/09/25 | 07:00:17 | 29 Sept 2025 | | AZN harmonises listing structure | RNS |
| 25/09/25 | 16:30:00 | 25 Sept 2025 | | Director/PDMR Shareholding | RNS |
| 22/09/25 | 07:05:00 | 22 Sept 2025 | | Koselugo recommended for EU approval | RNS |
| 22/09/25 | 07:00:12 | 22 Sept 2025 | | Tezspire Recommended for Approval in EU for CRSwNP | RNS |
| 17/09/25 | 07:05:00 | 17 Sept 2025 | | Saphnelo met primary endpoint in TULIP-SC | RNS |
| 17/09/25 | 07:00:12 | 17 Sept 2025 | | Update on RESOLUTE Phase III trial | RNS |
| 01/09/25 | 15:00:00 | 1 Sept 2025 | | Total Voting Rights | RNS |
| 28/08/25 | 15:00:00 | 28 Aug 2025 | | Holding(s) in Company | RNS |
| 26/08/25 | 15:00:00 | 26 Aug 2025 | | Holding(s) in Company | RNS |
| 21/08/25 | 15:00:00 | 21 Aug 2025 | | Holding(s) in Company | RNS |
| 18/08/25 | 15:00:00 | 18 Aug 2025 | | Director/PDMR Shareholding | RNS |
| 15/08/25 | 15:00:01 | 15 Aug 2025 | | Holding(s) in Company | RNS |
| 12/08/25 | 15:00:00 | 12 Aug 2025 | | Holding(s) in Company | RNS |
| 01/08/25 | 15:00:01 | 1 Aug 2025 | | Total Voting Rights | RNS |
| 29/07/25 | 07:00:12 | 29 Jul 2025 | | H1 and Q2 2025 results | RNS |
| 24/07/25 | 07:00:10 | 24 Jul 2025 | | Gefurulimab nanobody met Phase III endpoints | RNS |
| 22/07/25 | 07:00:07 | 22 Jul 2025 | | AstraZeneca plans to invest $50bn in the US | RNS |
| 16/07/25 | 07:00:07 | 16 Jul 2025 | | Update on anselamimab in AL amyloidosis | RNS |
| 14/07/25 | 07:00:11 | 14 Jul 2025 | | Baxdrostat met primary endpt in BaxHTN PhIII trial | RNS |
| 04/07/25 | 07:00:06 | 4 Jul 2025 | | Imfinzi approved in the EU for bladder cancer | RNS |
| 01/07/25 | 15:00:00 | 1 Jul 2025 | | Total Voting Rights | RNS |
| 24/06/25 | 07:00:08 | 24 Jun 2025 | | Datroway approved in US for EGFRm lung cancer | RNS |
| 13/06/25 | 09:30:00 | 13 Jun 2025 | | AstraZeneca enters into collaboration with CSPC | RNS |
| 12/06/25 | 15:00:01 | 12 Jun 2025 | | Director/PDMR Shareholding | RNS |
| 06/06/25 | 07:00:10 | 6 Jun 2025 | | Fixed-duration Calquence approved in EU for 1L CLL | RNS |
| 02/06/25 | 15:05:00 | 2 Jun 2025 | | Block listing Interim Review | RNS |
| 02/06/25 | 15:00:01 | 2 Jun 2025 | | Total Voting Rights | RNS |
| 27/05/25 | 07:00:07 | 27 May 2025 | | Imfinzi recommended in EU for bladder cancer | RNS |
| 23/05/25 | 10:00:00 | 23 May 2025 | | Director/PDMR Shareholding | RNS |
| 21/05/25 | 13:45:00 | 21 May 2025 | | Director Declaration | RNS |
| 20/05/25 | 07:00:09 | 20 May 2025 | | Acquisition of EsoBiotec completed | RNS |
| 09/05/25 | 07:00:05 | 9 May 2025 | | Imfinzi improved DFS in early bladder cancer | RNS |
| 07/05/25 | 07:30:00 | 7 May 2025 | | Enhertu improved pCR in early-stage breast cancer | RNS |
| 06/05/25 | 07:00:14 | 6 May 2025 | | Calquence combination approved in EU for 1L MCL | RNS |
